Aptorum Group (APM) Net Asset Value

Corporate company logo of Aptorum (APM)

The asset value of Aptorum Group Limited (APM), currently tracked on the chart at 0.02, is supported by the seamless operation of research centers and adherence to trial deadlines. The business focuses on developing drugs for rare and infectious pathologies, leveraging orphan status to protect profits. The financial stability of Aptorum Group Limited is based on a diversified portfolio of independent scientific projects.

APM Aptorum Group Limited Book Capitalization (07/04/2022 - 07/20/2026)

Financial and market metric breakdowns for Aptorum (APM)

- price and consensus price forecast:
Stock Quotes Aptorum Group Limited|APM - Price Target Chart
- market capitalization data:
Market Valuation Aptorum Group Ltd|APM - Enterprise Value
- book capitalization data:
Accounting Value of a Share Aptorum Group|APM - Book Capitalization|Market Capitalization to Book Value Ratio aptorumgroup.com|APM - Aggregate Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Aptorum Group Limited|APM - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Aptorum Group Limited|APM - Company Aggregate Debts|Debts to Book Capitalization Aptorum Group Ltd
Fundamental company valuation:Aptorum Group Limited
Flagship merchandise of aptorumgroup.com

To objectively assess the operational efficiency of Aptorum Group Limited, investors must separate market noise from the actual value of net assets. Analyzing the dynamics of the balance sheet capital structure reveals the difference between total assets and liabilities, which is critical for a biopharmaceutical company lacking stable cash flow and relying on external financing and R&D investments.

Competitors of Aptorum Group Limited

HLN: Company Net Assets|Company Book Value Kenvue Inc. (KVUE)|veronapharma.com (VRNA) - Net Asset Value|MENS - Book Capitalization|Accounting Value of Company Ligand Pharmaceuticals Incorporated|Book Capitalization AMRX|Book Capitalization PRGO (Perrigo Corp)|Company Book Value Alvotech|liquidia.com - Accounting Value of Company|GLPG: Company Book Value|ANIP - Company Net Assets|MNKD: Book Capitalization|Book Capitalization Amphastar Corp|PCRX - Company Net Assets|Accounting Value of Company SPRY|Theravance Biopharma, Inc. - Company Book Value|Total Stockholders' Equity Aquestive Therapeutics Inc AQST|Company Net Assets scPharmaceuticals (SCPH)|Total Net Assets Tectonic Therapeutic Inc. TECX|Book Capitalization Tonix Pharmaceuticals (TNXP)|SXTC - Accounting Value of Company|Book Capitalization EPRX|BHST (BioHarvest Sciences, Inc.) - Total Stockholders' Equity|EXOZ - Company Book Value|Accounting Value of Company Oramed Pharma|Book Capitalization ENTX|Book Capitalization HYFT (ipatherapeutics.com)|ABVC BioPharma, Inc. (ABVC) - Company Book Value|CPIX - Net Asset Value|Company Net Assets Quantum BioPharma Limited QNTM|FGEN: Total Net Assets|Company Book Value TELO|RANI (Rani Therapeutics Holdings, Inc.) - Total Stockholders' Equity|SNYR - Company Book Value|Accounting Value of Company Rallybio Corp. (RLYB)|Company Net Assets LEXX|Book Capitalization PULM (Pulmatrix Corporation)|Pheton Holdings - Company Book Value|LYRA - Company Net Assets|Company Net Assets Impact BioMedical Inc (IBO)|TNFA - Accounting Value of Company|Book Capitalization YCBD (cbdmd.com)|PRFX (PainReform Corp) - Book Value of Business|CYTO - Company Book Value|Accounting Value of Company LIPO|OptiNose - Company Book Value|Total Stockholders' Equity Pieris Pharmaceuticals Inc PIRS|Company Net Assets PROC (Procaps Group SA)|Petros Pharma - Book Capitalization|Company Book Value Qilian International|acelyrin.com (SLRN) - Net Asset Value|Company Net Assets TFF Pharmaceuticals, Inc. TFFP